Financial analysts have established a target price of $79.05 for BridgeBio Pharma, Inc. (NASDAQ: BBIO), indicating a generally positive outlook for the biopharmaceutical company....
Shares of Xometry, Inc. (NASDAQ: XMTR) have received a consensus recommendation of “Hold” from ten brokerages currently covering the stock, according to MarketBeat. Research...